Search results for "carriers"

showing 10 items of 391 documents

Mechanistic basis for unexpected bioavailability enhancement of polyelectrolyte complexes incorporating BCS class III drugs and carrageenans

2013

The objective of this study was to investigate the potential of λ-carrageenan to work as an absorption modifying excipient in combination with formulations of BCS class 3 substances. Trospium chloride was used as a model BCS class 3 substance. Polyelectrolyte complexes of trospium and λ-carrageenan were produced by layer-by-layer complexation. A λ-carrageenan-containing formulation was administered either in capsules size 9 to rats by gavage or directly into ligated intestinal loops of rats. Exceptionally strong variations were observed in the plasma concentrations of the rats that received λ-carrageenan compared to the control group, but enhanced plasma concentrations were observed only in…

MaleCell Membrane PermeabilityNortropanesBiological AvailabilityPharmaceutical ScienceExcipientMuscarinic AntagonistsAbsorption (skin)In Vitro TechniquesBenzilatesCarrageenanTight JunctionsElectrolyteschemistry.chemical_compoundMucoadhesionmedicineAnimalsHumansIntestinal MucosaRats WistarDrug CarriersChromatographyUssing chamberReproducibility of ResultsGeneral MedicinePermeationPolyelectrolyteRatsCarrageenanBioavailabilityMucusJejunumIntestinal AbsorptionSolubilitychemistryCaco-2 CellsBiotechnologymedicine.drugEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Poly(hydroxyethylaspartamide) derivatives as colloidal drug carrier systems

2003

Abstract Poly(hydroxyethylaspartamide) (PHEA) derivatives bearing at the polyaminoacidic backbone poly(ethyleneglycol) (2000 or 5000 Da) or both poly(ethyleneglycol) and hexadecylalkylamine as pendant moieties were investigated as polymeric colloidal drug carriers. The ability of the PHEA derivatives to solubilize hydrophobic drugs was investigated using paclitaxel, amphotericin B and methotrexate. The results demonstrated that the drug solubility depends on both macromolecule composition and drug physicochemical properties. In particular, PEG/hexadecylalkylamine co-grafting increased significantly the solubilization properties of PHEA for the considered drugs while the conjugation of PEG o…

MaleDrug CarriersMice Inbred BALB CCarrier systemCell SurvivalStereochemistryPharmaceutical ScienceBiological activityDosage formMicechemistry.chemical_compoundDrug Delivery SystemsPaclitaxelchemistryPharmacokineticsCell Line TumorDrug deliveryPEG ratioAnimalsColloidsPeptidesDrug carrierNuclear chemistryJournal of Controlled Release
researchProduct

Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.

2005

Hepatitis C virus is not cleared after primary infection in 50-85% of subjects exposed to hepatitis C virus. Anti-viral treatment during the early phase of infection significantly enhances the likelihood of a sustained clearance of hepatitis C virus. Although, a variety of autoimmune-related side effects have been observed during interferon therapy for chronic hepatitis, immuno-mediated adverse reactions have not been reported during treatment of acute hepatitis C. We describe the case of a patient who developed acute hepatitis C virus infection and, while receiving pegylated interferon alpha-2b monotherapy, developed a severe polymyositis. This case illustrates the potential risk of autoim…

MaleHepatitis C virusHepacivirusAcute hepatitis CAlpha interferonAutoimmunityHepacivirusInterferon alpha-2medicine.disease_causeIFNPolymyositisPolyethylene GlycolAntiviral AgentsVirusPolyethylene GlycolsPegylated interferonInterferonmedicineHumansDrug CarrierCreatine KinasePolymyositiAntiviral AgentDrug CarriersHepaciviruHepatologybiologybusiness.industryGastroenterologyInterferon-alphaHepatitis CRecombinant ProteinMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CRecombinant ProteinsAcute hepatitis C; Hepatitis C virus; IFN; Polymyositis; Acute Disease; Antiviral Agents; Autoimmunity; Creatine Kinase; Drug Carriers; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymyositis; RNA Viral; Recombinant Proteins; GastroenterologyPolymyositisImmunologyAcute DiseaseRNA ViralbusinessHepatitis C virumedicine.drugHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Polymeric Nanocarriers for Magnetic Targeted Drug Delivery: Preparation, Characterization, and in Vitro and in Vivo Evaluation

2013

In this paper the preparation of magnetic nano- carriers (MNCs), containing superparamagnetic domains, is reported, useful as potential magnetically targeted drug delivery systems. The preparation of MNCs was performed by using the PHEA-IB-p(BMA) graft copolymer as coating material through the homogenization−solvent evaporation method. Magnetic and nonmagnetic nanocarriers containing flutamide (FLU-MNCs) were prepared. The prepared nanocarriers have been exhaustively characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), and magnetic measurements. Biological evaluation was performed by in vitro cytotoxicity and cell uptake tests and in vivo biodistribution …

MaleMaterials sciencePharmaceutical ScienceAntineoplastic AgentsNanotechnologyMagneticsDrug Delivery SystemsDynamic light scatteringIn vivoCell Line TumorDrug DiscoveryLNCaPAnimalsHumansDistribution (pharmacology)Tissue DistributionParticle SizeRats WistarMagnetite NanoparticlesDrug Carriersequipment and suppliesmagnetic nanocarrier magnetic targeting flutamide superparamagnetic nanoparticlesFlutamideIn vitroRatsTargeted drug deliverySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBiophysicsMolecular MedicineNanocarriersPeptideshuman activitiesSuperparamagnetismMolecular Pharmaceutics
researchProduct

A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience

2004

Objectives To evaluate in a retrospective analysis the efficacy and safety of a 6 day course of liposomal amphotericin B (L-AmB) in infantile cases of Mediterranean visceral leishmaniasis (VL) diagnosed over a 10 year period in Italy. Patients and methods Patients included were diagnosed as having VL consecutively admitted from December 1992 to December 2001 at four main referral children's hospitals in Italy and treated with six intravenous doses of 3 mg/kg L-AmB given on days 1-5 and 10 (a total dose of 18 mg/kg). Demographic data, nutritional status, underlying diseases, clinical and laboratory findings, and therapy outcome were considered. Results A total of 164 HIV-negative children (m…

MaleMicrobiology (medical)medicine.medical_specialtyAdolescentFeverAntiprotozoal AgentsFluorescent Antibody TechniqueNutritional Statusitaly; leishmania infantum; therapyBone MarrowRecurrenceAmphotericin BInternal medicineAmphotericin BmedicineHumansPharmacology (medical)ChildAdverse effectleishmaniasisRetrospective StudiesPharmacologyDrug Carriersbiologybusiness.industryInfantRetrospective cohort studyLeishmaniasismedicine.diseasebiology.organism_classificationSurgeryRegimenTreatment OutcomeInfectious DiseasesVisceral leishmaniasisItalyEl NiñoChild PreschoolLiposomesLeishmaniasis VisceralFemaleLeishmania infantumbusinessmedicine.drug
researchProduct

Nitrosoureas Modes of Action and Perspectives in the Use of Hormone Receptor Affine Carrier Molecules

1989

Mechanisms of DNA adduct formation by antineoplastic 2-chloroethyl-N-nitrosoureas (CNUs) and of DNA damage induced by these compounds are discussed. CNUs are alkylating agents that form DNA-DNA cross-links as well as 2-chloroethylated and 2-hydroxyethylated adducts, the N-7-position of guanine being the predominantly alkylated site. A close correlation exists between the potential of a given compound to induce DNA-DNA cross-links and its antineoplastic effectiveness. However, levels of DNA-DNA cross-linking in bone marrow and extent of myelosuppression as measured in rodents are also closely correlated. The design of new cross-linking analogues capable of directing the antineoplastically re…

MaleNeoplasms Hormone-DependentDNA damageGuaninemedicine.medical_treatmentAntineoplastic AgentsReceptors Cell SurfaceNitrosourea CompoundsAdductStructure-Activity Relationshipchemistry.chemical_compoundBone MarrowmedicineAnimalsHumansRadiology Nuclear Medicine and imagingDrug Carriersbusiness.industryMammary Neoplasms ExperimentalProstatic NeoplasmsEstrogensHematologyGeneral MedicineSteroid hormoneOncologyMechanism of actionBiochemistrychemistryHormone receptormedicine.symptombusinessDNAHormoneActa Oncologica
researchProduct

Risk Profiles and Penetrance Estimations in Multiple Endocrine Neoplasia Type 2A Caused by Germline RET Mutations Located in Exon 10

2010

Multiple endocrine neoplasia type 2 is characterized by germline mutations in RET. For exon 10, comprehensive molecular and corresponding phenotypic data are scarce. The International RET Exon 10 Consortium, comprising 27 centers from 15 countries, analyzed patients with RET exon 10 mutations for clinical-risk profiles. Presentation, age-dependent penetrance, and stage at presentation of medullary thyroid carcinoma (MTC), pheochromocytoma, and hyperparathyroidism were studied. A total of 340 subjects from 103 families, age 4-86, were registered. There were 21 distinct single nucleotide germline mutations located in codons 609 (45 subjects), 611 (50), 618 (94), and 620 (151). MTC was present…

MalePHEOCHROMOCYTOMAendocrine system diseasesMEDULLARY-THYROID CARCINOMAAdrenal Gland NeoplasmsMultiple Endocrine Neoplasia Type 2aPenetrancemedicine.disease_causePHENOTYPEGermlineExon0302 clinical medicinemedullary thyroid carcinomaMEN2BMEN2AChildGenetics (clinical)GeneticsAged 80 and overMutationHyperparathyroidismLife SciencesExonsMiddle AgedCARRIERSPenetranceCANCERPROPHYLACTIC THYROIDECTOMY3. Good healthgenotype-phenotypeFAMILYMEN2030220 oncology & carcinogenesisChild PreschoolFemaleAdultAdolescent030209 endocrinology & metabolismMultiple endocrine neoplasia type 2BiologyPheochromocytoma03 medical and health sciencesYoung AdultGermline mutationGeneticsmedicineHumansThyroid NeoplasmsCodonGerm-Line MutationAgedNeoplasm StagingProto-Oncogene Proteins c-retCancerHIRSCHSPRUNG-DISEASEPROTOONCOGENEmedicine.diseaseGENECarcinoma NeuroendocrineCancer researchRETHuman Mutation
researchProduct

Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir.

2001

Acyclovir-loaded polyethyl-2-cyanoacrylate (PECA) nanospheres were prepared by an emulsion polymerization process in the micellar phase and characterized. The influence of the presence of nonionic surfactant as well as other substances [i.e., 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CyD) and poly(ethylene glycol) (PEG)], on formulation parameters and loading capacity was investigated. In particular, the presence of PEG resulted in an increase of mean size and size distribution. To obtain PEG-coated PECA nanospheres with a mean size of200 nm, Pluronic F68 at concentrations1.5% (w/v) should be used during preparation. The presence of PEG also resulted in a change in zeta potential, from -25…

MalePharmaceutical ScienceEmulsion polymerizationAcyclovirBiological AvailabilityEyeAntiviral AgentsDosage formPolyethylene Glycolschemistry.chemical_compoundPEG ratioZeta potentialMucoadhesionOrganic chemistryAnimalsCyanoacrylatesParticle SizeDrug Carrierstechnology industry and agricultureMicrospheresBioavailabilitychemistryRabbitsDrug carrierEthylene glycolNuclear chemistryJournal of pharmaceutical sciences
researchProduct

Polyhydroxyethylaspartamide-based micelles for ocular drug delivery

2009

In this paper three copolymers of polyhydroxyethylaspartamide (PHEA), bearing in the side chains polyethylene glycol (PEG) and/or hexadecylamine (C(16)) (PHEA-PEG, PHEA-PEG-C(16) and PHEA-C(16) respectively) have been studied as potential colloidal drug carriers for ocular drug delivery. The physical characterization of all three PHEA derivatives, using the Langmuir trough (LT) and micellar affinity capillary electrophoresis (MACE) techniques allowed to assume that whereas alone PHEA backbone is an inert polymer with respect to the interactions with lipid membranes and drug complexation, when PHEA chains are grafted with long alkyl chains like C(16) or in combination C(16) chains and hydrop…

MalePolymersAdministration TopicalBiological AvailabilityPharmaceutical SciencePolyethylene glycolMicelleDexamethasonePermeabilityPolyethylene Glycolschemistry.chemical_compoundocular drug delivery systemIn vivoPEG ratioAnimalsColloidsNetilmicinAminesLipid bilayerMicellesDrug CarriersChromatographyChemistryEpithelium Cornealtechnology industry and agricultureHydrocarbonsBioavailabilityDrug deliverypolymeric micelles amphiphilic copolymersRabbitsPeptidesDrug carrierConjunctiva
researchProduct

Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study

2017

Background and Aim The universal hepatitis B vaccination for infants and 12-year-old adolescents (the latter limited to the first 12 years of application) was launched in Italy in 1991. Twenty-three years later we evaluated the impact of the vaccination campaign on the burden of HBsAg-positive chronic liver diseases (CLD). Material and Methods 513 HBsAg-positive chronic carriers referring to 16 Italian liver units were investigated and compared with HBsAg carriers enrolled in previous surveys. Results The proportion of inactive carriers decreased from 20.0% in 2001 to 3.3% in 2014, while that of cirrhotic patients increased from 22.6 to 33.2%. Regarding the age class 0–33 (fully covered by …

MaleTime FactorsCirrhosisSettore MED/09 - Medicina InternaHbv vaccination0302 clinical medicinechronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccinationMedicine030212 general & internal medicineChildAged 80 and overVaccinationMiddle AgedVaccinationInfectious DiseasesItalyLiverCarrier StateFemale030211 gastroenterology & hepatologyHbsag carrierAdultHepatitis B virusAdolescentYoung Adult03 medical and health sciencesHepatitis B ChronicChronic hepatitisVirologyHumansHBsAg-positive chronic hepatitis clinical presentationHepatitis B Vaccineschronic hepatitis BHepatitis B AntibodiesHBsAg-positive chronic hepatitisAgedHBsAg chronic carrierHBV vaccinationImmunization Programsbusiness.industrychronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; virology; infectious diseasesInfantchronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; Virology; Infectious Diseasesmedicine.diseaseVirologyCross-Sectional StudiesHBsAg chronic carriersMulticenter studyHepatitis b vaccinationHBsAg-positive chronic hepatitibusiness
researchProduct